Lopressor
(Metoprolol)ApprovedSmall molecule
Metoprolol is a beta-blocker used to treat high blood pressure, angina (chest pain), and heart rhythm problems. It works by slowing your heart rate and reducing the workload on your heart.[2] Lopressor is currently approved and in use across 35 indications[4].[1]
Lopressor is one of 672 small molecule programs targeting Prader-Willi syndrome. It is currently in Approved.
35
Indications
110
Total Trials
10
Active Trials
671
Competitors
7
FDA Applications
NDA/BLA/ANDA regulatory filings
2
Patents
Pipeline
Status by Indication[4][1]
Indication
Showing 10 of 34 indications
Competition
Competitive Landscape
206 competitors in Heart Failure
#DrugCompanyPhaseTrials
1Lopressor
BBp Consulting, Inc
Approved
Medrol
PfizerPreclinical
Activase
RochePreclinical
Zemplar
AbbViePreclinical
Adriamycin
PfizerPreclinical
Xifaxan
SSalix
Preclinical
Statin
Bristol-Myers SquibbPreclinical
Neo-Synephrine
EExela Pharma Sciences, LLC.
Preclinical
GLP-1
RRigshospitalet, Denmark
Preclinical
Optimal Medical Therapy
HHelios Health Institute GmbH
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Atrial Fibrillation7 trials
Show 4 more trials
RATe Control in Atrial Fibrillation
Completed·—·Phase 3·NCT00313157·80 enrolled
Rate Control in Atrial Fibrillation II
Completed·—·Phase 4·NCT02695992·122 enrolled
Hypertension6 trials
Show 3 more trials
Heart Failure5 trials
Show 2 more trials
Interaction4 trials
Sarpogrelate Drug Interaction
Completed·—·Phase 1·NCT02097511·9 enrolled
Show 1 more trial
66 more indications
Atopic Dermatitis3 trials
Acute Coronary Syndrome3 trials
Renal Denervation in Patients After Acute Coronary Syndrome
Unknown status·MMeshalkin Research Institute of Pathology of Circulation·Phase 2·NCT01901549·80 enrolled
Tics3 trials
Function2 trials
Heart2 trials
Ventricular Function2 trials
Cardiomyopathy2 trials
Hypertensive2 trials
Paroxysmal atrial fibrillation2 trials
Type 2 Diabetes2 trials
Chronic Obstructive Pulmonary Disease2 trials
Essential Hypertension1 trial
Arrhythmia1 trial
Treatment of Ventricular Tachyarrhythmias Refractory To Shock With Beta Blockers: The SHOCK and BLOCK Trial
Terminated·—·Phase 2·NCT00401882·7 enrolled
Coronary Atherosclerosis1 trial
Effect of Evolocumab on Coronary Atherosclerosis
Completed·—·Phase 3·NCT03689946·55 enrolled
Kidney Transplant1 trial
Ventricular arrhythmia1 trial
Hypertrophic Cardiomyopathy1 trial
Effect of Metoprolol in Post Alcohol Septal Ablation Patients With Hypertrophic Cardiomyopathy
Completed·—·Phase 4·NCT04133532·22 enrolled
General Anesthetic1 trial
Kidney Disease1 trial
African American Study of Kidney Disease and Hypertension
Completed·NNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)·Phase 3·NCT04364139·1,094 enrolled
Extubation1 trial
Beta-blocker Before Extubation
Withdrawn·—·N/A·NCT00563238
Concentration1 trial
Cytokine Release Syndrome1 trial
Metoprolol Treatment for Cytokine Release Syndrome in Patients Treated With Chimeric Antigen Receptor T Cells
Unknown status·—·Phase 1/2·NCT04082910·30 enrolled
Diabetes Mellitus1 trial
Midazolam1 trial
Heart Rate Variability1 trial
Sinus Surgery1 trial
Syncope1 trial
Adult1 trial
Metabolic Syndrome1 trial
Platelet Reactivity1 trial
Subarachnoid Hemorrhage1 trial
Cirrhosis1 trial
ESS1 trial
Impact of Nebivolol on Central Aortic Pressure
Withdrawn·—·N/A·NCT01051947
Blood Pressure Variability1 trial
The Effects of Nifedipine and Metoprolol on Blood Pressure Variability in Northern Chinese
Unknown status·FFirst Affiliated Hospital of Harbin Medical University·Phase 2/3·NCT02513927·40 enrolled
AML1 trial
Metabolism1 trial
Vasovagal syncope1 trial
Radiofrequency Ablation1 trial
Radiofrequency Ablation of Symptomatic Frequent Ventricular Premature Complexes in Pediatric Population
Unknown status·MMeshalkin Research Institute of Pathology of Circulation·Phase 2/3·NCT02772354·124 enrolled
Myocardial Protection1 trial
Acute Respiratory Distress Syndrome1 trial
Metoprolol in Acute Respiratory Distress Syndrome (MAIDEN)
Recruiting·CConsorcio Centro de Investigación Biomédica en Red (CIBER)·Phase 3·NCT05847517·350 enrolled
Mitral regurgitation1 trial
Patent foramen ovale1 trial
Comparison of the Effect of Medication Therapy in Alleviating Migraine With Patent Foramen Ovale
Unknown status·—·Phase 4·NCT05546320·1,000 enrolled
Vascular Function1 trial
Sympathetic and Vascular Function in Takotsubo Syndrome
Completed·—·Phase 1/2·NCT05768542·31 enrolled
Psoriatic Arthritis1 trial
Lipid Emulsion1 trial
Sleep Apnea1 trial
Cardiomyopathy, Hypertrophic1 trial
Regulatory
FDA Approval Timeline[5]
Jan 1, 1982
LOPRESSOR
NDA NDA017963
Mar 30, 1984
LOPRESSOR
NDA NDA018704
Dec 27, 1989
LOPRESSOR
NDA NDA019786
Feb 5, 2001
TOPROL-XL
NDA NDA019962
Jan 26, 2018
KAPSPARGO SPRINKLE
NDA NDA210428
Apr 10, 2025
LOPRESSOR
NDA NDA219373
Aug 28, 2025
LOPRESSOR
NDA NDA218698
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Lopressor drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Metoprolol. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]
- [7]
Details
Drug Info
Quick Facts
- Mechanism of Action
- Beta-1 Adrenergic Receptor Antagonist[3]
- Modality
- Small molecule[3]
- Highest Phase
- Approved[1]
- Company
- BBp Consulting, Inc